Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients

Kidney International

Volumn 66, Issue 1, 2004, Pages 295-302

  Sengoelge, Gürkan ^a   Rainer, Verena ^b   Kletzmayr, Josef ^b   Jansen, Martin ^b   Derfler, Kurt ^b   Födinger, Manuela ^b   Hörl, Walter H ^b   Sunder Plassmann, Gere ^b  

^a Division of Nephrology and Dialysis   (Austria)

^b NONE

Author keywords

Anemia; Bleomycin detectable iron; Immune apheresis; Iron (III) sucrose; Iron deficiency

Indexed keywords

BLEOMYCIN; FERRIC HYDROXIDE SUCROSE; IRON COMPLEX; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; APHERESIS; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY FUNCTION; PRIORITY JOURNAL;

EID: 3042808472     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00731.x     Document Type: Article

References (63)

1. KNÖBL P, DERFLER K: Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 77(Suppl 1):57-64, 1999
2. HAAS M, BÖHMIG GA, LEKO-MOHR Z, et al: Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 17:1503-1508, 2002
3. LACZIKA K, KNAPP S, DERFLER K, et al: Immunoadsorption in Good-pasture's syndrome. Am J Kidney Dis 36:392-395, 2000
4. SCHNEIDER M, GAUBITZ M, PERNIOK A: Immunoadsorption in systemic connective tissue diseases and primary vasculitis. Ther Apher 1:117-120, 1997
5. SCHOEN H, FOEDINGER D, DERFLER K, et al: Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol 134:706-710, 1998
6. GRANINGER M, SCHMALDIENST S, DERFLER K, GRANINGER WB: Immunoadsorption therapy (therasorb) in patients with severe lupus erythematosus. Acta Med Austriaca 29:26-29, 2002
7. FINSTERER J, DERFLER K: Immunoadsorption in multifocal motor neuropathy. J Immunother 22:441-442, 1999
8. NAKAMURA Y, YOSHIDA K, ITOH S, et al: Immunoadsorption plasmapheresis as a treatment for pregnancy complicated by systemic lupus erythematosus with positive antiphospholipid antibodies. Am J Reprod Immunol 41:307-311, 1999
9. WEISS G: Iron, infection and anemia-a classical triad. Wien Klin Wochenschr 114:357-367, 2002
10. VANRENTERGHEM Y, PONTICELLI C, MORALES JM, et al: Prevalence and management of anemia in renal transplant recipients: A European survey. Am J Transplant 3:835-845, 2003
11. GROOTVELD M, BELL JD, HALLIWELL B, et al: Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem 264:4417-4422, 1989
12. RICHTER WO, DONNER MG, SELMAIER A, et al: Efficacy and safety of immunoglobulin apheresis. ASAIO J 43:53-59, 1997
13. GROB D, SIMPSON D, MITSUMOTO H, et al: Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 45:338-344, 1995
14. SCHAUMANN D, WELCH-WICHARY M, VOSS A, et al: Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur J Clin Invest 26:1033-1038, 1996
15. SUNDER-PLASSMANN G, HÖRL WH: Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis 38(Suppl 1):S20-25, 2001
16. FISHBANE S, KOWALSKI EA: The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 13:381-384, 2000
17. CHANDLER G, HARCHOWAL J, MACDOUGALL IC: Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38:988-991, 2001
18. YEE J, BESARAB A: Iron sucrose: The oldest iron therapy becomes new. Am J Kidney Dis 40:1111-1121, 2002
19. PATRUTA SI, HÖRL WH: Iron and infection. Kidney Int 55(Suppl 69):S125-130, 1999
20. GUO D, JABER BL, LEE S, et al: Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 58:134-142, 2002
21. SHAH SV, ALAM MG: Role of iron in atherosclerosis. Am J Kidney Dis 41(Suppl 1):S80-83, 2003
22. SULLIVAN JL: Iron therapy and cardiovascular disease. Kidney Int 55(Suppl 69):S135-137, 1999
23. GARTSIDE PS, GLUECK CJ: The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: The prospective NHANES I follow-up study. J Am Coll Nutr 14:71-79, 1995
24. HOEN B, PAUL-DAUPHIN A, HESTIN D, KESSLER M: EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9:869-876, 1998
25. HOEN B, PAUL-DAUPHIN A, KESSLER M: Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 57:457-461, 2002
26. BATEY RG, LAI CHUNG FONG P, SHAMIR S, SHERLOCK S: A non-transferrin-bound serum iron in idiopathic hemochromatosis. Dig Dis Sci 25:340-346, 1980
27. GRAHAM G, BATES GW, RACHMILEWITZ EA, HERSHKO C: Nonspecific serum iron in thalassemia: Quantitation and chemical reactivity. Am J Hematol 6:207-217, 1979
28. PARKKINEN J, VON BONSDORFF L, PELTONEN S, et al: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15:1827-1834, 2000
29. ROOYAKKERS TM, STROES ES, KOOISTRA MP, et al: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32(Suppl 1):9-16, 2002
30. DEICHER R, ZIAI F, COHEN G, et al: High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 64:728-736, 2003
31. PATRUTA SI, EDLINGER R, SUNDER-PLASSMANN G, HÖRL WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998
32. SENGOELGE G, KLETZMAYR J, FERRARA I, et al: Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 14:2639-2644, 2003
33. HALLIWELL B, GUTTERIDGE JM: Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 186:1-85, 1990
34. MCCORD JM: Iron, free radicals, and oxidative injury. Semin Hematol 35:5-12, 1998
35. WORKING PARTY FOR EUROPEAN BEST PRACTICE GUIDELINES FOR THE MANAGEMENT OF ANAEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE: European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14(Suppl 5):1-50, 1999
36. SUNDER-PLASSMANN G, HÖRL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
37. KOSCH M, SCHAEFER RM: Intravenous iron therapy. Wien Klin Wochenschr 115:380-384, 2003
38. KOOISTRA MP, KERSTING S, GOSRIWATANA I, et al: Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 32(Suppl 1):36-41, 2002
39. JANSEN M, SCHMALDIENST S, BANYAI S, et al: Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 112:91-97, 2001
40. GUTTERIDGE JM, ROWLEY DA, HALLIWELL B: Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Detection of 'free' iron in biological systems by using bleomycin-dependent degradation of DNA. Biochem J 199:263-265, 1981
41. VAN WYCK DB, CAVALLO G, SPINOWITZ BS, et al: Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 36:88-97, 2000
42. SUNDER-PLASSMANN G, HÖRL WH: Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Safety 17:241-250, 1997
43. TUOMAINEN TP, DICZFALUSY U, KAIKKONEN J, et al: Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med 35:922-928, 2003
44. ZHOU XJ, LASZIK Z, WANG XQ, et al: Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 80:1905-1914, 2000
45. MUMBY S, MARGARSON M, QUINLAN GJ, et al: Is bleomycin-detectable iron present in the plasma of patients with septic shock? Intensive Care Med 23:635-639, 1997
46. PEPPER JR, MUMBY S, GUTTERIDGE JM: Transient iron-overload with bleomycin-detectable iron present during cardiopulmonary bypass surgery. Free Radic Res 21:53-58, 1994
47. SAHLSTEDT L, EBELING F, VON BONSDORFF L, et al: Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 113:836-838, 2001
48. COLLINS HL: The role of iron in infections with intracellular bacteria. Immunol Lett 85:193-195, 2003
49. BULLEN JJ: The significance of iron in infection. Rev Infect Dis 3:1127-1138, 1981
50. CORTI MC, GURALNIK JM, SALIVE ME, et al: Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 79:120-127, 1997
51. MILLER M, HUTCHINS GM: Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 272:231-233, 1994
52. BAER DM, TEKAWA IS, HURLEY LB: Iron stores are not associated with acute myocardial infarction. Circulation 89:2915-2918, 1994
53. DANESH J, APPLEBY P: Coronary heart disease and iron status: Metaanalyses of prospective studies. Circulation 99:852-854, 1999
54. DUFFY SJ, BIEGELSEN ES, HOLBROOK M, et al: Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103:2799-2804, 2001
55. GAENZER H, MARSCHANG P, STURM W, et al: Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 40:2189-2194, 2002
56. LEE TS, SHIAO MS, PAN CC, CHAU LY: Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 99:1222-1229, 1999
57. KIECHL S, WILLEIT J, EGGER G, et al: Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study. Circulation 96:3300-3307, 1997
58. DE VALK B, ADDICKS MA, GOSRIWATANA I, et al: Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest 30:248-251, 2000
59. BREUER W, CABANTCHIK ZI: A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 299:194-202, 2001
60. ESPOSITO BP, BREUER W, SIRANKAPRACHA P, et al: Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 102:2670-2677, 2003
61. COLLINS AJ, LI S, ST PETER W, et al: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12:2465-2473, 2001
62. SELIGMAN PA, SCHLEICHER RB: Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 45:898-901, 1999
63. ESPOSITO BP, BREUER W, SLOTKI I, CABANTCHIK ZI: Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 32(Suppl 1):42-49, 2002